Squamous cell carcinoma

Global Lung Cancer Screening Software Market Report 2022: Growing Awareness about Screening Programs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The Global Lung Cancer Screening Software Market is segmented based on Cancer Type, Diagnosis Type, End-Users, and Geography.

Key Points: 
  • The Global Lung Cancer Screening Software Market is segmented based on Cancer Type, Diagnosis Type, End-Users, and Geography.
  • By Cancer Type, the market is classified into Non-Small Cell Lung Cancer, and Small Cell Lung Cancer.
  • The report presents a detailed Ansoff matrix analysis for the Global Lung Cancer Screening Software Market.
  • The report offers a comprehensive evaluation of the Global Lung Cancer Screening Software Market.

Genprex to Present at Upcoming December Investor Conference

Retrieved on: 
Friday, December 2, 2022

AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

Key Points: 
  • Ms. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors at the RHK Disruptive Growth Conference.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.

60th ANNUAL AUA AWARD WINNERS ANNOUNCED

Retrieved on: 
Thursday, December 1, 2022

BALTIMORE, Dec. 1, 2022 /PRNewswire/ -- The American Urological Association (AUA) announced today the list of 2023 award recipients. The winners will be recognized at the Association's Annual Meeting in Chicago, Illinois, next April marking the 60th anniversary of the awards program. The ceremony will celebrate physician researchers and educators for their contributions to the field of medicine, the specialty of urology and the AUA. 

Key Points: 
  • The winners will be recognized at the Association's Annual Meeting in Chicago, Illinois, next April marking the 60th anniversary of the awards program.
  • Lifetime Achievement Award: The Lifetime Achievement Award is presented annually to an individual for outstanding contributions to advance the mission and goals of the AUA.
  • Diversity & Inclusion Award: The Diversity & Inclusion Award is presented annually to an AUA member for outstanding impact on urologic diversity.
  • Gold-Headed Cane Award: The Gold-Headed Cane Award is presented to a senior urologist distinguished by outstanding contributions to the profession and to the AUA.

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Thursday, December 1, 2022

Patients enrolled in the study will be treated with CTX-471 in combination with KEYTRUDA with the goal of restoring response.

Key Points: 
  • Patients enrolled in the study will be treated with CTX-471 in combination with KEYTRUDA with the goal of restoring response.
  • We are very pleased to be making progress on our CTX-471 clinical program with dosing of the first patient in the combination arm with KEYTRUDA, said Thomas Schuetz, M.D., Ph.D., Chief Executive Officer and Scientific Founder of Compass.
  • CTX-471 has completed a Phase 1 dose escalation and cohort expansion study, where it was shown to be well-tolerated.
  • Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.

SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model

Retrieved on: 
Thursday, December 1, 2022

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from a preclinical in vivo study for its highly selective CDK9 inhibitor, GFH009, that demonstrate robust inhibition of tumor growth in a mouse xenograft model of small cell lung cancer (SCLC).

Key Points: 
  • GFH009 treated mice exhibited a 40.4% decrease in mean tumor growth compared to the control group in this very aggressive cancer model which had a tenfold increase in average tumor volume over 20 days.
  • Strongest effects were observed with GFH009 in combination with olaparib, with mean tumor growth decreased by 72.3%.
  • Treatment with olaparib alone resulted in a 30.2% mean decrease in tumor growth.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.

Actinic Keratosis Treatment Global Market Report 2022: Future Pipeline Medications and Further Use of Combination Therapy Promise Growth Moving Forward - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030., expanding at a CAGR of 4.1% from 2022 to 2030.

Key Points: 
  • The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030., expanding at a CAGR of 4.1% from 2022 to 2030.
  • The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment.
  • Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.
  • In addition, future pipeline medications and the increased use of combination therapy are key market drivers.

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Retrieved on: 
Wednesday, November 30, 2022

As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.

Key Points: 
  • As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.
  • Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023.
  • ONCR-021 is Oncorus lead candidate from its self-amplifying RNA platform intended to allow for intravenous (IV) administration.
  • At Oncorus, we are focused on driving innovation in RNA medicines by developing next-generation immunotherapies to stimulate the immune system and transform outcomes for cancer patients.

Theralase Releases Q322 Interim Financial Statements

Retrieved on: 
Tuesday, November 29, 2022

Theralase plans to commence GLP toxicology studies in animals in 4Q2022.

Key Points: 
  • Theralase plans to commence GLP toxicology studies in animals in 4Q2022.
  • Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations and a COVID-19 vaccine.
  • All forward-looking statements are made as of the date hereof and are subject to change.
  • Except as required by law, the Company assumes no obligation to update such statements.

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

Retrieved on: 
Tuesday, November 29, 2022

The first patient is expected to be enrolled and dosed in H1 of calendar year 2023, after completing the necessary ethics and regulatory steps.

Key Points: 
  • The first patient is expected to be enrolled and dosed in H1 of calendar year 2023, after completing the necessary ethics and regulatory steps.
  • Urothelial cancer is a type of cancer in the bladder or urinary tract.
  • Under the Agreement, Immutep and Merck KGaA, Darmstadt, Germany will jointly fund the INSIGHT-005 study.
  • Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immuteps large pharmaceutical partners.

Global Small Cell Lung Cancer Clinical Trial Pipeline Highlights - 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 29, 2022

The "Global Small Cell Lung Cancer Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Small Cell Lung Cancer Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report Small Cell Lung Cancer Pipeline Highlights - 2022, provides the most up-to-date information on key pipeline products within the global Small Cell Lung Cancer market.
  • It covers emerging therapies for Small Cell Lung Cancer in active clinical development stages including early and late stage clinical trials.
  • The report provides Small Cell Lung Cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.